Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663330 | 0.85 | DPP4 (0.43) | GPR119SCN9ACTSSCTSKSCN3A | |
| SCHEMBL6444465 | 0.85 | SCN9A (0.44) | GPR119SCN9ACTSSCTSKDPP4 | |
| SCHEMBL4955095 | 0.73 | DPP4 (0.51) | SCN9ACTSSCTSKDPP4DPP8 | |
| SCHEMBL8289111 | 0.73 | DPP4 (0.51) | SCN9ACTSSCTSKDPP4DPP8 | |
| SCHEMBL6444466 | 0.72 | DPP4 (0.48) | SCN9ACTSSCTSKDPP4DPP8 | |
| SCHEMBL14421765 | 0.71 | KLK5 (0.48) | SCN9ACTSSCTSKDPP4DPP8 | |
| SCHEMBL4915475 | 0.71 | CTSS (0.53) | SCN9ACTSSCTSKPTPN1 | |
| SCHEMBL4915481 | 0.71 | CTSS (0.53) | SCN9ACTSSCTSKPTPN1 | |
| SCHEMBL4915478 | 0.71 | CTSS (0.53) | SCN9ACTSSCTSKPTPN1 | |
| SCHEMBL4917131 | 0.70 | CTSS (0.55) | SCN9ACTSSCTSKPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1604662-A1 | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | GPR119 7/4885SCN9A 110/4885CTSS 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.